CTI BioPharma Corp (NASDAQ:CTIC) reported financial results for the first quarter ended March 31, 2015. “After reporting positive top-line results from the PERSIST-1 …
CTI BioPharma Corp. (NASDAQ:CTIC) and Baxter International Inc.
In a research report issued today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on CTI BioPharma Corp (NASDAQ:CTIC) with a $4.50 price target, …
Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Cell Therapeutics (NASDAQ:CTIC) with a $4.50 price target, which implies an upside of …
In a research report issued today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Cell Therapeutics (NASDAQ:CTIC) and raised his price target …
In a research report issued today, H.C.
In a research note published today, Janney Capital analyst Kimberly Lee maintained a Buy rating on Cell Therapeutics (NASDAQ:CTIC) with a $4 fair value, following collaboration agreement with …
In a research report released today, H.C.
In a research note published yesterday, Roth Capital analyst Debjit Chattopadhyay reiterated coverage with a Buy rating on shares of CTI Biophrarma Corp. (CTIC) …
In a report released Tuesday, Roth Capital analyst Debjit Chattopadhyay reiterated coverage on CTI BioPharma Corp (CTIC) with a Buy rating and a $4.00 price target, following yesterday’s news …
